In the past, organizations working in different pockets of the health sector made decisions according to their own business priorities. But as pharmaceutical and life sciences pipelines rebound, consumer choice and provider cost-savings incentives are driving change in the industry’s commercial model. As US specialty drug spending hits an all-time high, purchasers, prescribers and patients are considering price as a key component of a drug’s expected health benefit.
read full article ›Two of the biggest pharmaceutical companies in the world did something unusual this week when they announced the introduction of breakthrough drugs: they charged less.
read full article ›Payers will be buying the way other industrial buyers do -- they'll comparison shop. It's crucial that biopharma provide them the appropriate measurement tools. If they don't, buyers will settle on the easiest point of comparison: price.
read full article ›It’s the Planck constant of the pharmaceutical industry: if you’re going to build a commercially successful drug, it needs to
read full article ›Paying a lot of money to get your drug to market first is, in most cases, going to be worth a lot less in a payer-engaged future than it was in the physician-dominated past.
read full article ›Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of resistance from drug companies and payers, stakeholders are finding other tools to help identify the appropriate choices.
read full article ›Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.
read full article ›Not all payers make their decisions the same way. Smart payer segmentation strategies are extremely important to successful biopharmas.
read full article ›Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.
read full article ›As physicians lose decision-making authority to payers, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs’ use.
read full article ›